BUY SYMBIOTEC PHARMALAB LTD — ICICI Securities
byICICI SecuritiesHorizon: NA (inferred 1 year)1 Oct 2026via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Broker’s call: Symbiotec Pharmalab (Buy)
NewsHbl·1 Oct · today
Symbiotec's subsidiary, Knovea Pharmaceutical, signed a strategic commercialization agreement with a global pharmaceutical company for Dual Chamber Vials.
BSE · Company Update·30 Sept · yesterday
Symbiotec Pharma shares jump 8% after US FDA report on Pithampur plant
NewsCnbc-Tv18·29 Sept · 2d ago
Symbiotec Pharmalab Limited announced its financial results for the first quarter ended June 30, 2026. The company reported consolidated revenues of Rs. 218.2 Crs and consolidated PAT of Rs. 14.1 Crs.
NSE · Press Release·21 Sept · 1w ago
Symbiotec Pharmalab Ltd has announced its financial results for the 1st Quarter ended June 30, 2026. The results are available on the company website.
BSE · Company Update·21 Sept · 1w ago
Symbiotec Pharmalab Limited announced the outcome of its Board Meeting held on September 21, 2026. The Board considered and approved the unaudited standalone and consolidated financial results for the
NSE · Outcome of Board Meeting·21 Sept · 1w ago
Symbiotec Pharmalab Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following a board meeting.
NSE · Outcome of Board Meeting·21 Sept · 1w ago
Symbiotec Pharmalab Ltd's Board of Directors approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The trading window will remain closed for 48 hours.
BSE · Board Meeting·21 Sept · 1w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.